New Delhi, Oct 6 (NationPress) - In a significant move, US pharmaceutical leader Eli Lilly has declared its intention to invest over $1 billion in India in the coming years, focusing on new contract manufacturing to enhance the nation's Make in India initiative.

This strategic investment aims to increase patient access to Eli Lilly's essential medications, which include treatments for obesity, diabetes, Alzheimer's, cancer, and autoimmune disorders globally.

“This investment showcases Lilly’s trust in India’s skilled workforce, solid infrastructure, and pro-business policies, while also advancing Lilly’s position as a global leader in life sciences. Together, we are forging a brighter future for healthcare and manufacturing. We take pride in supporting Lilly’s growth in India and wish them ongoing success,” stated Nivruti Rai, Managing Director & CEO of Invest India, Ministry of Commerce & Industry.

Additionally, Lilly plans to set up a new manufacturing and quality facility in Hyderabad. This hub will provide advanced technical capabilities and oversight for Lilly’s contract manufacturing network across the nation.

“The expansion of Lilly in Hyderabad underscores the city’s rise as a center for global healthcare innovation. With the recent launch of its innovation and technology site, new manufacturing collaborations, and the establishment of a manufacturing and quality hub, Lilly is rapidly scaling its operations in Telangana, solidifying the state’s reputation as a prime destination for innovative healthcare investments,” mentioned A. Revanth Reddy, Hon’ble Chief Minister of Telangana.

The company also announced plans to “immediately begin” hiring for various roles such as engineers, chemists, analytical scientists, quality control and assurance experts, as well as management positions, thereby enhancing India’s skilled workforce.

“This investment reinforces our belief in India as a key hub for capability development within our global network,” remarked Patrik Jonsson, Executive Vice President and President of Lilly International, Eli Lilly and Company.